Related Experiment Videos
Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA
Stefan G Sarafianos1, Arthur D Clark, Kalyan Das
1Center for Advanced Biotechnology and Medicine, 679 Hoes Lane, Piscataway, NJ 08854-5638, USA.
The EMBO Journal
|November 29, 2002
Summary
HIV-1 reverse transcriptase resistance to AZT (3'-azido-3'-deoxythymidine) involves enhanced AZTMP excision. Crystal structures reveal how this excision and translocation mechanism occur, offering insights into drug resistance.
Area of Science:
- Biochemistry
- Structural Biology
- Virology
Background:
- HIV-1 reverse transcriptase (RT) is a key target for antiretroviral therapy.
- Azidothymidine (AZT) resistance is a significant clinical challenge, often mediated by enhanced excision of AZT monophosphate (AZTMP).
- Understanding the structural basis of AZT resistance and RT translocation is crucial for developing new therapies.
Purpose of the Study:
- To elucidate the structural mechanisms underlying AZT resistance by examining AZTMP excision.
- To investigate the structural differences between pre-translocation (N) and post-translocation (P) complexes of HIV-1 RT.
- To gain insights into the molecular basis of RT translocation.
Main Methods:
- Determined crystal structures of HIV-1 RT in pre-translocation (N) and post-translocation (P) complexes.
- Analyzed structures at 3.0 and 3.1 A resolution.
- Performed docking of a deoxynucleotide triphosphate (dNTP) into the P complex.
Main Results:
- Crystal structures of N and P complexes provide atomic-level detail of AZTMP excision.
- Steric crowding in the P complex upon dNTP binding favors the N complex, the substrate for excision.
- Structural differences between N and P complexes implicate the YMDD loop in the translocation process.
Conclusions:
- The YMDD loop acts as a 'springboard' facilitating primer terminus movement during translocation.
- Structural insights explain enhanced AZTMP excision, a key mechanism of AZT resistance.
- Understanding these mechanisms can guide the design of novel HIV-1 RT inhibitors.